Quince Therapeutics, Inc. (QNCX : NASDAQ)
Common Stock
Follow QNCX
QNCX
Quince Therapeutics, Inc.
WealthAwesomePerformance
1 Day
+14.34%
1 Week
+16.47%
1 Month
+21.71%
YTD
+113.84%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$32.27M
52W High
$910.00
52W Low
$15.10
P/E Ratio
-
50 Day MA
$30.84
200 Day MA
$82.02
Beta
1.33
Dividend Yield
-
Performance history
QNCX returns since 2026
Quince Therapeutics, Inc. has traded since Jun 2026 in our data. Its deepest fall was −27.2% (Oct 2026 to Nov 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*+113.8%
* Partial year (first year of data, or year to date).
$10,000 invested in QNCX
- 2026 (start of our data)$21,384
- All-time high in our data
- $40 on Oct 20, 2026 · now −4.1%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past QNCX? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $33.27 | $39.92 | $32.56 | $38.62 | $38.62 | 166,300 |
| 11/9/2026 | $29.50 | $35.12 | $29.50 | $33.77 | $33.77 | 125,200 |
| 11/6/2026 | $28.84 | $31.09 | $28.84 | $31.00 | $31.00 | 33,600 |
| 11/5/2026 | $30.47 | $30.91 | $27.03 | $29.31 | $29.31 | 53,400 |
| 11/4/2026 | $33.80 | $34.15 | $31.14 | $31.67 | $31.67 | 57,900 |
| 11/3/2026 | $32.95 | $33.55 | $31.85 | $33.16 | $33.16 | 60,300 |
| 11/2/2026 | $32.94 | $34.09 | $31.02 | $33.55 | $33.55 | 96,500 |
| 10/30/2026 | $30.67 | $34.40 | $30.00 | $32.95 | $32.95 | 98,000 |
| 10/29/2026 | $32.86 | $33.76 | $30.51 | $31.62 | $31.62 | 64,300 |
| 10/28/2026 | $32.32 | $33.40 | $31.00 | $32.95 | $32.95 | 62,900 |
Analyst Price Targets
Based on analyst covering QNCX · as of Oct 19, 2026
Wall Street analysts forecast QNCX stock price to rise 94.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$75.00
+94.2% Upside
Current Price
US$38.62
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on QNCX's historical volatility
30-Day Vol
117.8%
Annualized
90-Day Vol
90.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$46.17
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$40.99 | US$27.30 – US$61.54 |
| 60 trading days | US$43.50 | US$24.48 – US$77.29 |
| 90 trading days | US$46.17 | US$22.84 – US$93.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-60.65M
- Profit Margin
- 0.00%
- ROE (TTM)
- -153.84%
- EPS (Diluted)
- -214.01
- Book Value
- -34.73
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About QNCX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| ESLA | Estrella Immunopharma Inc. | $0.75 | +45.40% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
Free with a Wealth Awesome account
Keep analysing QNCX, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.